Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation

J Parkinsons Dis. 2018;8(3):399-403. doi: 10.3233/JPD-181360.

Abstract

Kufor-Rakeb syndrome (KRS)/PARK9 presents with autosomal recessive young onset Parkinson's disease (YOPD), spastic paraparesis, abnormal eye movements and facial myokymia. KRS is caused by homozygous/compound heterozygous inactivating mutations in ATP13A2. Two affected siblings (born to non-consanguineous Jewish parents) presenting a similar KRS phenotype (onset age 27, 23), carried compound heterozygous pathogenic variants in ATP13A2: c.217_218insG and c.3057delC. Allele frequency of the c.3057delC mutation was about 100 times higher in Ashkenazi controls in our study (1/190 = 0.00526) and in the Genome Aggregation Database, (GnomAD, 27/10132 = 0.002665) versus non-Ashkenazi controls worldwide in GnomAD (9/264566 = 0.000034018, p < 0.0001). The c.217_218insG mutation is novel and not found in controls or GnomAD. The c.3057delC mutation should be included in the genetic workup of Ashkenazi YOPD patients.

Keywords: Ashkenazi; Genetics; Kufor-Rakeb syndrome; PARK9; Parkinsonism; Parkinson’s disease.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Child
  • Female
  • Humans
  • Male
  • Mutation
  • Parkinsonian Disorders / genetics*
  • Phenotype
  • Proton-Translocating ATPases / genetics*
  • Siblings
  • Young Adult

Substances

  • ATP13A2 protein, human
  • Proton-Translocating ATPases

Supplementary concepts

  • Kufor-Rakeb syndrome